As reported by Kelsey Rolfe of Benefits Canada, reforms to the Patented Medicines Pricing Review Board (PMPRB) have been upheld by the Federal Court. This decision followed an application for judicial review by Innovative Medicines Canada and 16 pharmaceutical companies who opposed the amendments which included:
In setting drug prices, a “basket” of 11 other countries (no longer including the US and Switzerland), that are similar to Canada’s population, economy and approach to health care, will be used to compare prices.
In establishing a price ceiling for a drug in Canada, the PMPRB will now have access […]
